Toggle Main Menu Toggle Search

Open Access padlockePrints

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection

Lookup NU author(s): Dr David Sheridan

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background & Aims Single nucleotide polymorphisms (SNPs) near the interferon lambda 3 (IFNL3, previously known as IL28B) region are the strongest baseline predictors of sustained virologic response (SVR) to pegylated interferon and ribavirin therapy in hepatitis C virus (HCV) genotype 1 infection. Whether IFNL3 SNPs influence treatment response in genotype 2 and 3 (HCV-2/3) infection remains controversial. This study sought to clarify in a large cohort, whether SNPs in the IFNL3 region are associated with treatment response in HCV-2/3 patients. Methods The cohort comprised 1002 HCV-2/3 Caucasians patients treated with pegylated interferon-alpha and ribavirin who underwent genotyping for the SNPs rs12979860 and rs8099917. Results Overall, 736 (73.5%) patients achieved SVR (81.9%, 67.9%, and 57.8% for rs12979860 CC, CT, and TT [p = 0.0001]; 78%, 68.7%, and 46.3% for rs8099917 TT, TG, and GG [p = 0.0001]). By logistic regression, both rs12979860 CC and rs8099917 TT were independent predictors of SVR with an odds ratio (OR) of 2.39 (1.19-3.81) p = 0.0001 and OR 1.85 (1.15-2.23) p = 0.0001, respectively. IFNL3 responder genotypes were more frequent in relapsers than null-responders (p = 0.0001 for both SNPs). On-treatment rapid virological response (RVR) was predictive of SVR only in those individuals with IFNL3 non-responder genotypes (rs12979860 CT/TT and rs8099917 TG/GG). Conclusions This adequately powered study in patients with HCV genotypes 2 or 3 infection clearly demonstrates that IFNL3 genotypes are the strongest baseline predictor of SVR, in keeping with the known association for genotype 1 infection. IFNL3 genotyping can aid in therapeutic decision making for these patients.


Publication metadata

Author(s): Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G

Publication type: Article

Publication status: Published

Journal: Journal of Hepatology

Year: 2014

Volume: 61

Issue: 2

Pages: 235-241

Print publication date: 01/08/2014

Online publication date: 24/04/2014

Acceptance date: 30/03/2014

ISSN (print): 0168-8278

ISSN (electronic): 1600-0641

Publisher: Elsevier

URL: https://doi.org/10.1016/j.jhep.2014.03.039

DOI: 10.1016/j.jhep.2014.03.039

PubMed id: 24768758


Altmetrics

Altmetrics provided by Altmetric


Share